Merck trims full-year profit outlook, beats Q1 estimates; shares slightly up

Published 24/04/2025, 11:42
© Reuters

Investing.com -- Merck & Co (NYSE:MRK) reported stronger-than-expected earnings for the first quarter while trimming its profit outlook for the full year. The company’s shares rose around 1% in premarket trading Thursday. 

The drugmaker reported Q1 earnings per share (EPS) of $2.22, exceeding the consensus estimate of $2.14.

Revenue for the period came in at $15.53 billion, also above expectations of $15.33 billion, but down 1.6% from the prior year.

Sales of Merck (NSE:PROR)’s cancer drug Keytruda increased 3.7% year-over-year to $7.21 billion but fell short of the $7.45 billion estimate.

Meanwhile, Gardasil revenue dropped sharply to $1.33 billion, a 41% decline, primarily due to weaker demand in China. This was partially offset by stronger demand in Japan and the U.S., along with improved pricing.

Operating expenses were broadly in line with forecasts. Adjusted SG&A expenses totaled $2.5 billion, slightly above the $2.47 billion estimate, while R&D spending reached $3.6 billion, matching projections.

“Our company made strong progress to start the year, with increasing contributions from our newer commercialized medicines and vaccines and continued advancement of our pipeline,” said Robert M. Davis, chairman and CEO of Merck.

“We are working with focus and urgency to both realize the full potential of our near-term opportunities and to rapidly progress the next wave of innovation that will positively impact the lives of patients and drive future value creation for all of our stakeholders.”

For the full year, Merck trimmed its adjusted EPS guidance to a range of $8.82 to $8.97 from the previous $8.88 to $9.03.

The company said the new outlook reflects the impact of a $0.06 per share charge related to a licensing agreement with Hengrui Pharma, as well as a $0.09 per share charge tied to a payment to LaNova for MK-2010.

The company maintained its revenue forecast of $64.1 billion to $65.6 billion, in line with the $65.1 billion consensus. However, it now expects an adjusted gross margin of about 82%, down from the earlier projection of 82.5%.

Merck’s guidance incorporates around $200 million in additional costs linked to U.S. and foreign-imposed tariffs, with China representing the most significant exposure.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.